Thyroid hormone-dependent oligodendroglial cell lineage genomic and non-genomic signaling through integrin receptors
Authors:
Open Access
- 5 September 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 934971
Abstract
Multiple sclerosis (MS) is a heterogeneous autoimmune disease whereby the pathological sequelae evolve from oligodendrocytes (OLs) within the central nervous system and are targeted by the immune system, which causes widespread white matter pathology and results in neuronal dysfunction and neurological impairment. The progression of this disease is facilitated by a failure in remyelination following chronic demyelination. One mediator of remyelination is thyroid hormone (TH), whose reliance on monocarboxylate transporter 8 (MCT8) was recently defined. MCT8 facilitates the entry of THs into oligodendrocyte progenitor cell (OPC) and pre-myelinating oligodendrocytes (pre-OLs). Patients with MS may exhibit downregulated MCT8 near inflammatory lesions, which emphasizes an inhibition of TH signaling and subsequent downstream targeted pathways such as phosphoinositide 3-kinase (PI3K)-Akt. However, the role of the closely related mammalian target of rapamycin (mTOR) in pre-OLs during neuroinflammation may also be central to the remyelination process and is governed by various growth promoting signals. Recent research indicates that this may be reliant on TH-dependent signaling through β1-integrins. This review identifies genomic and non-genomic signaling that is regulated through mTOR in TH-responsive pre-OLs and mature OLs in mouse models of MS. This review critiques data that implicates non-genomic Akt and mTOR signaling in response to TH-dependent integrin receptor activation in pre-OLs. We have also examined whether this can drive remyelination in the context of neuroinflammation and associated sequelae. Importantly, we outline how novel therapeutic small molecules are being designed to target integrin receptors on oligodendroglial lineage cells and whether these are viable therapeutic options for future use in clinical trials for MS.Keywords
Funding Information
- Trish Multiple Sclerosis Research Foundation
This publication has 192 references indexed in Scilit:
- Engineering triiodothyronine (T3) nanoparticle for use in ischemic brain strokeDrug Delivery and Translational Research, 2012
- Glycolytic oligodendrocytes maintain myelin and long-term axonal integrityNature, 2012
- Rheb1 Is Required for mTORC1 and Myelination in Postnatal Brain DevelopmentDevelopmental Cell, 2011
- Essential Molecular Determinants for Thyroid Hormone Transport and First Structural Implications for Monocarboxylate Transporter 8Journal of Biological Chemistry, 2010
- Signaling mechanisms in thyroid hormone-induced cardiac hypertrophyVascular Pharmacology, 2010
- IntegrinsCell and tissue research, 2009
- Neural recognition molecules CHL1 and NB‐3 regulate apical dendrite orientation in the neocortex via PTPαThe EMBO Journal, 2007
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- Activation of the subventricular zone in multiple sclerosis: Evidence for early glial progenitorsProceedings of the National Academy of Sciences, 2007
- IntegrinsCell, 2002